SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Arthur Klausner will sit on a panel at the 11th Annual Drug Delivery Technologies and Deal Making Conference, sponsored by SRI
News | 09. 26. 2006
